DMD and cystic fibrosis: Even though the results of clinical trials in CF patients are inconclusive, recent evidence suggests that ataluren treatment can modestly slow disease progression in patients with nonsense mutation DMD, even though the primary endpoints of some clinical trials were not met [144].